ResMedRMDEarnings & Financial Report
ResMed Inc. is a medical equipment company based in San Diego, California, and founded in Australia. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. Resmed produced hundreds of thousands of ventilators and bilevel devices to help treat the respiratory symptoms of patients with COVID-19.
RMD Q4 FY2026 Key Financial Metrics
Revenue
$1.4B
Gross Profit
$878.7M
Operating Profit
$491.7M
Net Profit
$392.6M
Gross Margin
61.8%
Operating Margin
34.6%
Net Margin
27.6%
YoY Growth
11.0%
EPS
$2.68
ResMed Q4 FY2026 Financial Summary
ResMed reported revenue of $1.4B (up 11.0% YoY) for Q4 FY2026, with a net profit of $392.6M (up 13.9% YoY) (27.6% margin). Cost of goods sold was $544.1M, operating expenses totaled $387.0M.
Key Financial Metrics
| Total Revenue | $1.4B |
|---|---|
| Net Profit | $392.6M |
| Gross Margin | 61.8% |
| Operating Margin | 34.6% |
| Report Period | Q4 FY2026 |
ResMed Annual Revenue by Year
ResMed annual revenue history includes year-by-year totals (for example, 2026 revenue was $5.6B).
ResMed Quarterly Revenue & Net Profit History
ResMed results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2026 | $1.4B | +11.0% | $392.6M | 27.6% |
| Q3 FY2026 | $1.4B | +10.8% | $398.7M | 27.9% |
| Q2 FY2026 | $1.4B | +11.0% | $392.6M | 27.6% |
| Q1 FY2026 | $1.3B | +9.1% | $348.5M | 26.1% |
| Q4 FY2025 | $1.3B | +10.2% | $379.7M | 28.2% |
| Q3 FY2025 | $1.3B | +7.9% | $365.0M | 28.3% |
| Q2 FY2025 | $1.3B | +10.3% | $344.6M | 26.9% |
| Q1 FY2025 | $1.2B | +11.1% | $311.4M | 25.4% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.22B | $1.28B | $1.29B | $1.35B | $1.34B | $1.42B | $1.43B | $1.42B |
| YoY Growth | 11.1% | 10.3% | 7.9% | 10.2% | 9.1% | 11.0% | 10.8% | 11.0% |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | Q4 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $7.22B | $7.14B | $7.57B | $8.17B | $8.31B | $8.50B | $8.78B | $8.50B |
| Liabilities | $2.03B | $1.89B | $2.02B | $2.21B | $2.19B | $2.18B | $2.29B | $2.18B |
| Equity | $5.20B | $5.25B | $5.55B | $5.97B | $6.12B | $6.32B | $6.49B | $6.32B |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|
| Operating CF | $325.5M | $308.6M | $578.7M | $538.8M | $457.3M | $339.7M |